[HTML][HTML] Good practice statements for antithrombotic therapy in the management of COVID‐19: guidance from the SSC of the ISTH
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors, JD Douketis… - Journal of Thrombosis …, 2022 - jthjournal.org
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
[PDF][PDF] Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors, JD Douketis, M Goldin… - 2022 - portailvasculaire.fr
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors… - … of thrombosis and …, 2022 - pubmed.ncbi.nlm.nih.gov
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
[HTML][HTML] Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors, JD Douketis… - … of Thrombosis and …, 2022 - ncbi.nlm.nih.gov
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH.
AC Spyropoulos, JM Connors, JD Douketis… - … of Thrombosis and …, 2022 - europepmc.org
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors… - … of Thrombosis and …, 2022 - Wiley Online Library
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …
[引用][C] Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors, JD Douketis… - Journal of Thrombosis …, 2022 - cir.nii.ac.jp
Good practice statements for antithrombotic therapy in the management of COVID‐19:
Guidance from the SSC of the ISTH | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Guidance from the SSC of the ISTH | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
[PDF][PDF] Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors, JD Douketis, M Goldin… - 2022 - en.iacld.com
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
[PDF][PDF] Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH
AC Spyropoulos, JM Connors, JD Douketis, M Goldin… - 2022 - iacld.com
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …
agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in …